|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
AU2353384A
(en)
|
1983-01-19 |
1984-07-26 |
Genentech Inc. |
Amplification in eukaryotic host cells
|
|
US4713339A
(en)
|
1983-01-19 |
1987-12-15 |
Genentech, Inc. |
Polycistronic expression vector construction
|
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
|
AU6029594A
(en)
|
1993-01-15 |
1994-08-15 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
|
IL113010A0
(en)
|
1994-03-31 |
1995-10-31 |
Pharmacia Ab |
Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
|
|
JPH11501506A
(ja)
|
1994-12-12 |
1999-02-09 |
ベス イスラエル デアコネス メディカル センター |
キメラ型サイトカインおよびその利用
|
|
WO1997003193A1
(en)
|
1995-07-11 |
1997-01-30 |
Chiron Corporation |
Novel factor viii:c polypeptide analogs with altered metal-binding properties
|
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
AT403764B
(de)
*
|
1996-03-15 |
1998-05-25 |
Immuno Ag |
Stabiler faktor viii/vwf-komplex
|
|
PT1754718E
(pt)
|
1996-04-24 |
2011-07-13 |
Univ Michigan |
Factor viii resistente à inactivação
|
|
US20040092442A1
(en)
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
JP4545928B2
(ja)
|
1998-04-27 |
2010-09-15 |
ジリップ・ファーマ・ビー．ブイ． |
第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US7615622B2
(en)
|
2001-01-12 |
2009-11-10 |
University Of Maryland, Baltimore |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
|
|
US7205278B2
(en)
|
2001-06-14 |
2007-04-17 |
The Scripps Research Institute |
Stabilized proteins with engineered disulfide bonds
|
|
US20080108560A1
(en)
|
2002-03-05 |
2008-05-08 |
Eli Lilly And Company |
Heterologous G-Csf Fusion Proteins
|
|
DE60332011D1
(de)
|
2002-04-29 |
2010-05-20 |
Sanquin Bloedvoorziening |
Antagonisten der interaktion zwischen faktor viii und lrp ("low-density lipoprotein receptor related protein")
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
WO2004075923A2
(en)
|
2003-02-26 |
2004-09-10 |
Nektar Therapeutics Al, Corporation |
Polymer-factor viii moiety conjugates
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
PT1624891E
(pt)
|
2003-05-06 |
2010-01-05 |
Syntonix Pharmaceuticals Inc |
Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
|
|
MXPA05013565A
(es)
|
2003-06-12 |
2006-03-09 |
Lilly Co Eli |
Proteinas de fusion analogas al glp-1.
|
|
JP2008504008A
(ja)
|
2003-12-31 |
2008-02-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
KR101468345B1
(ko)
|
2004-11-12 |
2014-12-03 |
바이엘 헬스케어 엘엘씨 |
Ｆｖｉｉｉ의 부위 지향 변형
|
|
CA2591852A1
(en)
|
2004-12-27 |
2006-07-06 |
Baxter International Inc. |
Polymer-von willebrand factor-conjugates
|
|
CA2604299A1
(en)
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation factor viii with enhanced stability and its derivates
|
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
|
CA2647314A1
(en)
|
2006-03-31 |
2007-11-08 |
Baxter International Inc. |
Pegylated factor viii
|
|
AU2007260185B2
(en)
|
2006-06-14 |
2013-01-31 |
Csl Behring Gmbh |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
|
AU2007338298B2
(en)
|
2006-12-22 |
2013-02-07 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
|
ES2392569T3
(es)
|
2007-06-13 |
2012-12-11 |
Csl Behring Gmbh |
Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
|
|
KR101648734B1
(ko)
|
2008-06-24 |
2016-08-18 |
체에스엘 베링 게엠베하 |
연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
|
|
KR101808751B1
(ko)
|
2009-11-13 |
2017-12-13 |
그리폴스 테라퓨틱스 인코포레이티드 |
폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
|
|
WO2013093760A2
(en)
|
2011-12-19 |
2013-06-27 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
DK2804623T3
(da)
|
2012-01-12 |
2019-11-11 |
Bioverativ Therapeutics Inc |
Kimære faktor viii-polypeptider og anvendelser deraf
|
|
WO2013120939A1
(en)
|
2012-02-15 |
2013-08-22 |
Csl Behring Gmbh |
Von willebrand factor variants having improved factor viii binding affinity
|
|
EP2841091A1
(en)
*
|
2012-04-24 |
2015-03-04 |
Novo Nordisk A/S |
Pharmaceutical composition suitable for treatment of haemophilia
|
|
JP2015515482A
(ja)
*
|
2012-04-24 |
2015-05-28 |
ノヴォ ノルディスク アー／エス |
血友病の治療に適する化合物
|
|
HRP20200007T1
(hr)
|
2012-07-11 |
2020-03-20 |
Bioverativ Therapeutics Inc. |
Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
|
|
EP2796145B1
(en)
|
2013-04-22 |
2017-11-01 |
CSL Ltd. |
A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
|
|
WO2014198699A2
(en)
|
2013-06-12 |
2014-12-18 |
Novo Nordisk A/S |
Compounds suitable for treatment of haemophilia
|
|
EP3152230B1
(en)
|
2014-06-06 |
2019-08-07 |
Octapharma AG |
Preparation comprising factor viii and von willebrand factor peptides
|
|
CA2953593C
(en)
|
2014-07-02 |
2023-09-26 |
Csl Limited |
Modified von willebrand factor
|
|
WO2016188905A1
(en)
|
2015-05-22 |
2016-12-01 |
Csl Behring Recombinant Facility Ag |
Methods for preparing modified von willebrand factor
|